Founded in 2012 by Luca Puccioni and Lucjan Samulowski, DocPlanner has achieved unicorn status with a valuation of $1B, backed by $141M in total funding from investors including RTAventures, Piton Capital and Goldman Sachs. With a projected revenue between $100M and $250M, the company is positioned for continued technological upgrades and market penetration in healthtech SaaS offerings.
Cyborg Score Rationale
Market-leading position in digital health appointment booking with significant scale (2M healthcare professionals, 260K customers), unicorn valuation, and strong VC backing. Recent investment (January 2026) demonstrates continued investor confidence. Established presence across 13 countries provides geographic diversification and competitive moat.
Top Insights
In January 2026, DocPlanner secured $33.8 million in new investment, reinforcing its position as a leading global provider of digital healthcare solutions.
The platform facilitates over 22 million patient appointments booked per month and handles scheduling, booking, communication and payments for over 30 million patients monthly.
Top competitors include Doctolib, Doctoralia and MioDottore.
DocPlanner Group has acquired 4 companies, with the latest acquisition being MyDr on January 11, 2023.
Named Competitors
Doctolib — Healthcare appointment booking and practice management platform
Doctoralia — Online platform for finding and booking doctor appointments
MioDottore — Italian doctor discovery and appointment booking platform
Recent Developments
(January 2026) Secured $33.8M in new investment round
(2023) Acquired MyDr in Polish market expansion
(2019) Series E funding round of $89.9M in May
Open the full interactive DocPlanner Group report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.